Clinical-Stage Companies / Shanghai Minwei Biotechnology

Shanghai Minwei Biotechnology

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

162

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Overweight , Obesity Healthy Volunteers Type 2 Diabetes Mellitus (T2DM) MASH - Metabolic Dysfunction-Associated Steatohepatitis Overweight or Obesity

Clinical Trials (20)

NCT07778693 Phase 3 NOT YET RECRUITING

Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity

Started: 9/1/2026

NCT07803822 Phase 2 RECRUITING

Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia

Started: 9/25/2026

NCT07801820 Phase 2 RECRUITING

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Started: 6/23/2026

NCT07791524 Phase 2 COMPLETED

Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity

Started: 1/5/2026

NCT07791654 Phase 2 COMPLETED

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity

Started: 8/23/2025

NCT07791537 Phase 2 ACTIVE NOT RECRUITING

Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight

Started: 12/26/2025

NCT07804810 Phase 2 COMPLETED

Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Started: 9/3/2025

NCT07804797 Phase 2 ACTIVE NOT RECRUITING

Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity

Started: 3/2/2026

NCT06938269 Phase 1 RECRUITING

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

Started: 6/18/2025

NCT06859853 Phase 1 RECRUITING

A Study to Evaluate MWN109 Injection in Healthy Subjects

Started: 3/17/2025

NCT07803809 Phase 1 RECRUITING

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Started: 4/26/2026

NCT07803835 Phase 1 RECRUITING

Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension

Started: 3/19/2026

NCT07634510 Phase 1 NOT YET RECRUITING

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

Started: 6/22/2026

NCT07779980 Phase 1 NOT YET RECRUITING

Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants

Started: 8/26/2026

NCT07787728 Phase 1 COMPLETED

Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity

Started: 7/14/2025

NCT07787611 Phase 1 COMPLETED

Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants

Started: 6/27/2025

NCT07787624 Phase 1 COMPLETED

Phase 1 Clinical Study of MWN109 Injection in Healthy Chinese Volunteers

Started: 12/18/2024

NCT07801326 Phase 1 COMPLETED

A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants

Started: 5/24/2026

NCT07801313 Phase 1 COMPLETED

Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers

Started: 12/19/2024

NCT07799025 Phase 1 ACTIVE NOT RECRUITING

Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects

Started: 7/7/2025

Drug Candidates

MWN109 tablet Subcutaneous single and mutiple dose MWX205 MWN109 1 MWN109 2 MWN109 3 MWN110 MWN109 4 MWN109 MWN105 1

Activity Status: Active

Last Trial Started: 9/25/2026

Last Trial Ended: 8/10/2026

Trials (12 months): 11

Completed Trials: 8

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.